Isabella Presch/LinkedIn
Aug 26, 2026, 18:27
Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
Isabella Presch, Senior Medical Director Rare diseases, Advanced therapies and Pediatrics at Fortrea, shared a post on LinkedIn:
“An important signal from the FDA: not every genome-editing program needs to start from zero.
The new draft guidance highlights how prior knowledge can be responsibly leveraged to advance development while maintaining rigorous standards for quality, safety, and efficacy. Encouraging progress for the future of rare disease innovation.
Potential Strategic Implications for Sponsors:
- Enable faster development across multiple genome-editing programs
- Reduce redundant CMC and nonclinical work
- Encourage early platform planning
- Increase the value of robust platform datasets
- particularly beneficial for rare disease, pediatric, and individualized therapy programs”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026